



Published in final edited form as:

Aust J Chem. 2020 ; 73(3): 246–251. doi:10.1071/CH19307.

A theoretical assessment of structure determination of multi-span membrane proteins by oriented sample solid-state NMR spectroscopy

Daniel K. Weber^{†,1}, Gianluigi Veglia^{†,‡}

[†]Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA

[‡]Department of Chemistry, University of Minnesota, Minneapolis, MN 55455, USA

Abstract

Oriented sample solid state NMR (OS-ssNMR) spectroscopy allows direct determination of the structure and topology of membrane proteins reconstituted into aligned lipid bilayers. While OS-ssNMR theoretically has no upper size limit, its application to multi-span membrane proteins has not been established since most studies have been restricted to single or dual span proteins and peptides. Here, we present a critical assessment of the application of this method to multi-span membrane proteins. We used molecular dynamics simulations to back-calculate [¹⁵N-¹H] separated local field (SLF) spectra from a G protein-coupled receptor (GPCR) and show that fully resolved spectra can be obtained theoretically for a multi-span membrane protein with currently achievable resonance linewidths.

Solid-state NMR (ssNMR) spectroscopy is the method of choice for obtaining high-resolution structural and dynamical information of membrane proteins embedded in native-like liquid crystalline lipid bilayers.^[1] Directionally-dependent dipolar couplings (DCs) and chemical shift anisotropy (CSA), which broaden signals in conventional solution NMR methods, are either averaged out by magic angle spinning (MAS) techniques or directly measured using oriented sample (OS) methods for structural restraints.^[2–6] MAS-ssNMR mostly removes these interactions by mechanically spinning samples in a rotor about an angle of 54.74° at high frequency (currently over 100 kHz) to resolve isotropic chemical shifts (CSs) with solution-like resolution. While increasingly popular, the application of MAS-ssNMR to membrane proteins has been limited primarily by low sensitivity as only a few microliters can be packed into high-speed rotors, much of which is composed by water and lipid. Furthermore, poorly-dispersed isotropic chemical shifts arising from transmembrane (TM) α -helical residues – a common issue for membrane protein NMR in general – often leads to poor resolution. OS-ssNMR, on the other hand, achieves comparable resolution by homogeneously orienting membrane proteins by either reconstitution into supported lipid bilayers (SLBs) or into systems that spontaneously align with magnetic

¹Corresponding author: dweber@umn.edu.

Conflicts of Interest

The authors declare no conflicts of interest.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

fields such as high- q bicelles^[7] or macrodiscs.^[8–9] Additionally, the anisotropic chemical shift tensor^[10] greatly enhances CS dispersion (and resolution), while sample volumes upwards of 100 μ L allows for milligram quantities of protein to be studied under physiological relevant lipid-protein ratios and hydration levels. An outstanding example was the use of OS-ssNMR spectroscopy to characterize the β -helical antibiotic channel-forming peptide Gramicidin A in lipid bilayers by Separovic and Cornell^[11–13] and later on the determination of its high-resolution structure by Cross and coworkers.^[14–15] OS-ssNMR has since advanced with improvements in theory, software and hardware such as the introduction of multidimensional separated local field (SLF) experiments,^[16–20] sensitivity-enhanced pulse sequences,^[21–22] simultaneous acquisition schemes,^[23] low- E probes,^[24] paramagnetic relaxation enhancement,^[25] structural calculation methods,^[26–33] higher magnetic fields^[34] and dynamic nuclear polarization.^[35–38] As a result, OS-ssNMR has been central to several notable structural studies including the M2 segments of the acetylcholine and N -methyl-D-aspartate (NMDA) receptors;^[39] the filamentous bacteriophage fd coat protein;^[40] the HIV channel-forming Vpu protein;^[41–42] the bacterial MerF mercury transporter;^[43–45] the Influenza A M2 proton channel;^[46] the β -barrel outer membrane protein OmpX from *Escherichia coli*;^[47] membrane-anchored cytochrome P450 metabolic enzymes;^[48] the cardiac regulatory protein phospholamban;^[49–50] the tuberculosis CrgA protein involved in cell division;^[51] the TM domains of the adaptive immune system's MHC II proteins;^[52–53] the TM domain of the p24 protein involved in vesicle sorting and transport;^[54] the Huntington 1–17 membrane anchor;^[55] cell-penetrating peptides;^[56–57] and recently an in-depth characterization into the dynamics of the dimeric triple-pass bacterial EmrE drug transporter^[58]. Despite its potential, difficult sample preparation and low resolution have generally limited OS-ssNMR to studies of peptides and small proteins. Recently, however, linewidths as narrow as 50 Hz are starting to be reported with the introduction of macrodiscs.^[9] Prompted by these advancements, we have devised a new method to test the feasibility of OS-ssNMR spectroscopy for multi-pass membrane proteins using computational approaches.

To assess this, we carried out molecular dynamics (MD) simulations and calculated the theoretical [¹⁵N-¹H] SLF spectrum of the seven transmembrane (TM) β_2 -adrenergic G-protein-coupled receptor (GPCR; PDB 3P0G)^[59] from an MD trajectory. SLF spectra correlate ¹⁵N CSs with ¹⁵N-¹H DCs of amide residues and are commonly acquired on uniformly ¹⁵N-labelled protein using PISEMA or SAMPI4 pulse sequences.^[16, 18, 22] Unlike isotropic CSs observed in solution NMR and MAS-ssNMR, which are positioned according to electronic shielding or deshielding of nuclei induced by the surrounding chemical environment, anisotropic CSs in OS-ssNMR directly relate to time-averaged orientations of the chemical shift tensor components ($\langle \vec{\delta}_{11} \rangle$, $\langle \vec{\delta}_{22} \rangle$, and $\langle \vec{\delta}_{33} \rangle$) with respect to the magnetic field vector (\vec{B}_0) and can be analyzed over an ensemble of MD snapshots similar to previously reported methods.^[60] For each frame, the tensor components were projected onto the amide plane of each residue (see Figure 1A), with $\vec{\delta}_{11}$ and $\vec{\delta}_{33}$ lying in-plane and a rotation of $\vec{\delta}_{33}$ by 17° (polar angle β) away from the N-H bond vector ($\vec{\mu}$).^[61] The

normalized time-averaged orientations of each component with respect to \vec{B}_0 (Z -axis of MD simulation) were used to find the ^{15}N CS (δ_{MD}) (Eqn 1):

$$\delta_{MD} = \delta_{11} \left(\vec{B}_0 \cdot \langle \vec{\delta}_{11} \rangle \right)^2 + \delta_{22} \left(\vec{B}_0 \cdot \langle \vec{\delta}_{22} \rangle \right)^2 + \delta_{33} \left(\vec{B}_0 \cdot \langle \vec{\delta}_{33} \rangle \right)^2 \quad (1)$$

where δ_{11} , δ_{22} and δ_{33} were 57.3, 81.2 and 228.1 ppm, respectively.^[62] Angular brackets denote time-averages. Correct determination of these values,^[63] along with proper chemical shift calibration,^[64] will strongly impact the agreement between experimental and MD-predicted spectra. Experimentally, however, the observed CS (δ) is also scaled by per-residue order parameters (S_{NH}), the order of the alignment medium (S_{memb}),^[41] rigid-body dynamics of the protein ($S_{protein}$),^[65–67] and the angle of the membrane normal with respect to \vec{B}_0 (θ_{memb}). The ^{15}N CS may then be adjusted according to Eqn 2:

$$\delta = (\delta_{MD} - \delta_{iso}) \cdot S_{NH} \cdot S_{align} \cdot \left(\frac{3 \cdot \cos^2 \theta_{memb} - 1}{2} \right) + \delta_{iso} \quad (2)$$

where $\delta_{iso} = (\delta_{11} + \delta_{22} + \delta_{33})/3$. S_{align} is a user-defined generalised order parameter to account for scaling due to $S_{protein}$ and S_{memb} , which may not be adequately sampled by the simulation. Like lipid C- ^2H order parameters,^[68] the S_{NH} parameter for each residue was estimated from Z -axis fluctuation of the amide N-H bond vector ($\vec{\mu}$) away from its time-averaged orientation, or director axis ($\langle \vec{\mu} \rangle$), and assuming fast-rotational diffusion, according to Eqn 3:

$$S_{NH} = \left\langle \frac{3(\vec{\mu} \cdot \langle \vec{\mu} \rangle)^2 - 1}{2} \right\rangle \quad (3)$$

Consequently, disorder due to $S_{protein}$ is implicit in S_{NH} if rigid-body (rocking) motions of the membrane protein are unrestrained during the MD simulation. These motions, however, are usually slow on MD simulation timescales (100–1000s ns) and restraining them, or aligning trajectories to starting coordinates, is recommended for faster convergence of CS and DC values.

Lastly, the ^{15}N - ^1H DC (ν_{MD}) was determined from the normalized time-average orientation of the N-H bond vector ($\vec{\mu}$) by Eqn 4:

$$\nu_{MD} = \frac{\nu_{||}}{2} \left(3 \left(\vec{B}_0 \cdot \langle \vec{\mu} \rangle \right)^2 - 1 \right) \quad (4)$$

where $\nu_{||}$ is the maximal DC and set to 10.735 kHz.^[27] The experimentally observable DC (ν) was then determined by Eqn 5:

$$\nu = \nu_{MD} \cdot S_{NH} \cdot S_{align} \cdot \left(\frac{3 \cdot \cos^2 \theta_{memb} - 1}{2} \right) \quad (5)$$

The analysis was implemented using custom Tcl code built on *VMD 1.9.3* functions^[69] and available at <https://github.com/weberdak/md2slf> (accessed June 9th 2019) along with *Python* scripts to convert peak lists to NMR spectra in *Sparky*^[70] format. The approach is analogous to restrained^[26] and unrestrained^[71] MD methods reported previously, but it is primarily intended as a post-processing method of MD trajectories to predict SLF spectra from pre-existing structural data rather than *de novo* structure calculation. Therefore, this method was developed for convenience in early stages of spectral assignment and experimental design. It is applicable to trajectories obtained from any simulation package and forcefield and does not require advanced accelerated sampling methods. In addition, it is easy to implement using freely available software, customizable parameters, and can generate data that can be directly compared to experimental results from magnetically aligned systems. For simplicity, CSs and DCs were computed only from the final ensemble averages of $\vec{\mu}$, $\vec{\delta}_{11}$, $\vec{\delta}_{22}$ and $\vec{\delta}_{33}$, with S_{NH} and user-defined parameters δ_{11} , δ_{22} , δ_{33} , ν_{\parallel} , S_{align} and θ_{memb} rather than at every frame of the trajectory as done previously.^[26, 71] While CS and DC distributions computed from these past studies provided some insight into the broad line shapes observed in SLF spectra from SLBs, they appear negligible for relatively dynamic magnetically aligned systems where structural and topological fluctuations observed on MD timescales are completely averaged out on NMR timescales to yield narrow linewidths.^[71] For this work, MD simulations were set up using the *CHARMM-GUI Membrane Builder* webserver^[72–73] and run using CHARMM36 forcefield parameters^[74–75] and the NAMD 2.12 simulation package.^[76] Proteins were embedded in a bilayer containing 75% DMPC and 25% POPC lipids to be consistent with experimental bicelle compositions used for magnetic alignment at room temperature.^[77]

To test the accuracy of MD-predicted CSs and DCs, their back-calculated average values from a 150 ns trajectory of SLN (PDB 1JDM^[78]) were compared against experimental SE-SAMPI4^[22] spectra using *unflipped* ($\theta_{memb} = 90.0^\circ$) bicelles^[25] (Figure 1B). A remarkable correlation was observed, with the largest deviation attributed to the terminal residue Y31. R^2 values of 0.59 and 0.62 were determined for CSs and DCs, respectively, which increases to 0.89 and 0.87 respectively if Y31 outliers are removed. The tilt angle of SLN was restrained in the simulation to the experimentally determined angle^[77] of 24° using 100 kcal/mol *tilt* collective variable restraints available in NAMD 2.12,^[76] while azimuthal fluctuations were left unrestrained. No adjustments of S_{align} (*i.e.*, set to 1.0) was required, suggesting that the MD simulation accounted for the primary sources of disorder. Experimental and calculated ^{15}N CS and ^{15}N - ^1H DC cross-peaks are overlaid in Figure 1C and produce PISA (*P*olar *I*ndex *S*lant *A*ngle) wheel patterns that reflect the periodicity of residues in an α -helix.^[30] The ability of MD-derived SLF spectra to predict deviations from idealized wheels is striking, especially the far-removed peak assigned to Asn4. These results demonstrate that MD-based predictions of SLF spectra may be a powerful alternative to PISA wheel simulation methods^[27] commonly used to assign and rationalize experimental data.

With the accuracy of MD-derived CSs and DCs established, the method was then applied to predict an SLF spectrum from a crystal structure of the β_2 -adrenergic GPCR in the active state (PDB 3P0G).^[59] The simulated GPCR structure was prepared as per previous MD

studies,^[79–80] with the stabilizing T4 lysozyme residues and G-protein mimetic Nb80 nanobody removed to save computation time. Drifts to the inactive state and slow-timescale rocking motions were suppressed by applying 10 kcal/mol *tilt* and *spinAngle* collective variable restraints on backbone atoms of all TM α -helices. MD-predicted peak positions were then used to simulate SLF spectra (Figure 2A) into *Sparky*^[70] format using the *NMRGlue*^[81] *Python* library. The spectral width of the simulated spectrum corresponded to the ¹⁵N frequency on a 14.1 T magnet (60.8 MHz) and peaks were represented as Gaussians of 50 Hz FWHM linewidth in CS and DC dimensions to approximate the narrowest linewidths currently reported.^[9] Nearly all of 276 backbone peaks simulated were fully resolved, demonstrating the potential for OS-ssNMR to capture high-resolution structural and topological information of large membrane proteins. More realistically, however, linewidths are often on the order of 100 to 200 Hz due to factors accompanying the complexity of larger systems, such as sample and structural inhomogeneity, slow-timescale motions,^[82] mosaic spread^[83] and multiple conformational states^[84], for which spectroscopists generally benefit from employing higher field strengths and selective labelling and unlabelling strategies.^[85–86] Additionally, simulated GPCR spectra were in the form of a *flipped* system achieved using either SLBs or bicelles and macrodiscs doped with lanthanides^[87] to obtain a parallel orientation of the normal of the bilayer with respect to the static magnetic field (\mathbf{B}_0). This essentially doubles resolution by increasing dispersion of CSs and DCs and eliminates line broadening arising from slow-timescale uniaxial rotational diffusion common of larger proteins.^[88–89]

Unlike SLN, PISA wheels are no longer clearly distinguishable in spectra of the GPCR due to crowding and peaks appear dispersed across the range of allowed combinations of CSs and DCs. To further rationalize the spectrum, peaks associated with residues central to each of the 10 helices were fit to ideal PISA models^[27] (Figure 2A) by an exhaustive search^[90] factoring in a general order parameter of 0.95 (typical of S_{NH}) and idealized backbone structural parameters (i.e., bonds and dihedral angles) averaged from the MD trajectory. As expected, TM helices oriented parallel to the magnetic field clustered downfield of the spectrum, while perpendicular intra- (ICL) and extra-cellular (ECL) helices occupied the upfield end. Several peaks clustered in the 110 to 130 ppm range, away from ideal PISA positions, were mostly from flexible and unstructured residues at juxtamembrane positions. Helical residues of TM7 and H8 were isolated in Figure 2B (see Figure 2C for nomenclature) and closely resemble two PISA wheels. It is noteworthy that at 3.5 Å the resolution of the GPCR crystal structure (PDB 3P0G) would not allow accurate computation of SLF peaks directly from deposited PDB coordinates as non-refined backbone atom positions produce very large errors in CS and DC values^[91] and do not reflect the time-averaged nature of the measurement. The power of MD-simulation to refine these errors was assessed using the convergence plot in Figure 2D. Here, the final 150 ns of equilibrated simulation was broken into 150 blocks. From the first equilibrated frame (at 50 ns), blocks of frames were successively added until the end of the trajectory (200 ns), with DC and CS values recomputed after the addition of each block. The average drift in cross-peak positions, over n cross-peaks, with each successive block ($+b$) was determined by Eqn 6:

$$SLF\ Drift = \sqrt{\frac{1}{n} \sum_i^n \left((CS_{i,+b} - CS_{i,-b})^2 + 10(DC_{i,+b} - DC_{i,-b})^2 \right)} \quad (6)$$

where DCs were scaled up by 10 to match CS dispersion. From this plot, convergence of SLF values was mostly complete from just a 50 ns ensemble. Per-residue contributions to the final SLF drift (Figure 2E) show that at 200 ns the best approximations are made for structured regions, while peak positions of dynamic residues will generally require longer timescales, or accelerated sampling schemes, to converge.

In conclusion, we demonstrated the potential for OS-ssNMR to obtain site-resolved topological and structural information for large multi-pass membrane proteins through MD-predicted [¹⁵N-¹H] SLF spectra of a GPCR. Realizing this potential in practice will hinge on further harnessing bicelles and macrodiscs as alignment media, which have been especially crucial for obtaining narrow linewidths,^[9] as well as providing hydration levels, lipid ratios and preparative routes more amendable to maintaining larger and more-complex proteins in a functional state. The successful use of these systems, however, remains challenging as variations in temperature, pH, lipid composition and the presence of membrane proteins can have unforeseen consequences on magnetic alignment properties. While these limitations are currently being addressed,^[92-93] traditionally used SLBs are still utilized as a robust method to mechanically align proteins.^[52, 94] Furthermore, the striking ability of MD simulations to accurately predict SLF spectra from existing structural data sets, even at low resolution, may position OS-ssNMR as a powerful complement to cryo-electron microscopy, which has proven highly successful for solving membrane protein structures in ground states. We envision an interplay between these two techniques may involve streamlined assignment of OS-ssNMR experiments to provide crucial insights into the function of membrane proteins embedded in fluid-phase lipid bilayers at physiological temperature.

Acknowledgements

This work was partially supported by the National Institutes of Health (GM64742 and HL144130 to G.V.) and the American Heart Association (19POST34420009 to D.W.).

References

1. Chipot C; Dehez F; Schnell JR; Zitzmann N; Pebay-Peyroula E; Catoire LJ; Miroux B; Kunji ERS; Veglia G; Cross TA; Schanda P, *Chem. Rev* 2018, 118, 3559. doi:10.1021/acs.chemrev.7b00570 [PubMed: 29488756]
2. Ladizhansky V, *Biochim. Biophys. Acta* 2017, 1865, 1577. doi:10.1016/j.bbapap.2017.07.004
3. Radoicic J; Lu GJ; Opella SJ, *Q. Rev. Biophys* 2014, 47, 249. doi:10.1017/S0033583514000080 [PubMed: 25032938]
4. van der Wel PCA, *Emerg. Top. Life Sci* 2018. doi:10.1042/ETLS20170088
5. Wylie BJ; Do HQ; Borcik CG; Hardy EP, *Mol. Phys* 2016, 114, 3598. doi:10.1080/00268976.2016.1252470
6. Opella SJ, *Biomed. Spectrosc. Imaging* 2014, 3, 81. doi:10.3233/BSI-140080 [PubMed: 26069880]
7. Sanders CR; Landis GC, *Biochemistry*. 1995, 34, 4030. doi:10.1021/bi00012a022 [PubMed: 7696269]
8. Park SH; Berkamp S; Cook GA; Chan MK; Viadiu H; Opella SJ, *Biochemistry*. 2011, 50, 8983. doi:10.1021/bi201289c [PubMed: 21936505]

9. Radoicic J; Park SH; Opella SJ, *Biophys. J* 2018, 115, 22. doi:10.1016/j.bpj.2018.05.024 [PubMed: 29914645]
10. Saitô H; Ando I; Ramamoorthy A, *Prog. Nucl. Magn. Reson. Spectrosc* 2010, 57, 181. doi:10.1016/j.pnmrs.2010.04.005 [PubMed: 20633363]
11. Cornell BA; Separovic F; Baldassi AJ; Smith R, *Biophys. J* 1988, 53, 67. doi:10.1016/S0006-3495(88)83066-2 [PubMed: 19431717]
12. Cornell BA; Weir LE; Separovic F, *Eur. Biophys. J* 1988, 16, 113. doi:10.1007/BF00255521 [PubMed: 2463153]
13. Smith R; Thomas DE; Separovic F; Atkins AR; Cornell BA, *Biophys. J* 1989, 56, 307. doi:10.1016/S0006-3495(89)82677-3 [PubMed: 2476189]
14. Ketchum R; Hu W; Cross T, *Science*. 1993, 261, 1457. doi:10.1126/science.7690158 [PubMed: 7690158]
15. Ketchum RR; Roux B; Cross TA, *Structure*. 1997, 5, 1655. doi:10.1016/S0969-2126(97)00312-2 [PubMed: 9438865]
16. Wu CH; Ramamoorthy A; Opella SJ, *J. Magn. Reson., Ser A* 1994, 109, 270. doi:10.1006/jmra.1994.1169
17. Nevzorov AA; Opella SJ, *J. Magn. Reson* 2003, 164, 182. doi:10.1016/S1090-7807(03)00240-4 [PubMed: 12932472]
18. Nevzorov AA; Opella SJ, *J. Magn. Reson* 2007, 185, 59. doi:10.1016/j.jmr.2006.09.006 [PubMed: 17074522]
19. Marassi FM; Gesell JJ; Valente AP; Kim Y; Oblatt-Montal M; Montal M; Opella SJ, *J. Biomol. NMR* 1999, 14, 141. doi:10.1023/A:1008391823293 [PubMed: 10427741]
20. Mote KR; Gopinath T; Traaseth NJ; Kitchen J; Gor'kov PL; Brey WW; Veglia G, *J. Biomol. NMR* 2011, 51, 339. doi:10.1007/s10858-011-9571-8 [PubMed: 21976256]
21. Gopinath T; Mote KR; Veglia G, *Prog. Nucl. Magn. Reson. Spectrosc* 2013, 75, 50. doi:10.1016/j.pnmrs.2013.07.004 [PubMed: 24160761]
22. Gopinath T; Veglia G, *J. Am. Chem. Soc* 2009, 131, 5754. doi:10.1021/ja900096d [PubMed: 19351170]
23. Gopinath T; Mote KR; Veglia G, *J. Biomol. NMR* 2015, 62, 53. doi:10.1007/s10858-015-9916-9 [PubMed: 25749871]
24. Gor'kov PL; Chekmenev EY; Li C; Cotten M; Buffy JJ; Traaseth NJ; Veglia G; Brey WW, *J. Magn. Reson* 2007, 185, 77. doi:10.1016/j.jmr.2006.11.008 [PubMed: 17174130]
25. Wang S; Gopinath T; Veglia G, *Methods*. 2018, 138–139, 54. doi:10.1016/j.ymeth.2017.12.017
26. De Simone A; Mote KR; Veglia G, *Biophys. J* 2014, 106, 2566. doi:10.1016/j.bpj.2014.03.026 [PubMed: 24940774]
27. Denny JK; Wang J; Cross TA; Quine JR, *J. Magn. Reson* 2001, 152, 217. doi:10.1006/jmre.2001.2405 [PubMed: 11567575]
28. Lapin J; Nevzorov AA, *J. Magn. Reson* 2018, 293, 104. doi:10.1016/j.jmr.2018.06.004 [PubMed: 29920407]
29. Lapin J; Nevzorov AA, *J. Biomol. NMR* 2019, 73, 229. doi:10.1007/s10858-019-00251-7 [PubMed: 31076969]
30. Marassi FM; Opella SJ, *J. Magn. Reson* 2000, 144, 150. doi:10.1006/jmre.2000.2035 [PubMed: 10783285]
31. Mascioni A; Eggimann BL; Veglia G, *Chem. Phys. Lipids* 2004, 132, 133. doi:10.1016/j.chemphyslip.2004.09.018 [PubMed: 15530454]
32. Nevzorov AA; Opella SJ, *J. Magn. Reson* 2003, 160, 33. doi:10.1016/S1090-7807(02)00138-6 [PubMed: 12565046]
33. Shi L; Traaseth NJ; Verardi R; Cembran A; Gao J; Veglia G, *J. Biomol. NMR* 2009, 44, 195. doi:10.1007/s10858-009-9328-9 [PubMed: 19597943]
34. Gan Z; Hung I; Wang X; Paulino J; Wu G; Litvak IM; Gor'kov PL; Brey WW; Lendi P; Schiano JL; Bird MD; Dixon IR; Toth J; Boebinger GS; Cross TA, *J. Magn. Reson* 2017, 284, 125. doi:10.1016/j.jmr.2017.08.007 [PubMed: 28890288]
35. Bechinger B, *eMagRes* 2018, 7, 25. doi:10.1002/9780470034590.emrstm1558

36. Salnikov E; Rosay M; Pawsey S; Ouari O; Tordo P; Bechinger B, *J. Am. Chem. Soc* 2010, 132, 5940. doi:10.1021/ja1007646 [PubMed: 20392100]
37. Salnikov ES; Abel S; Karthikeyan G; Karoui H; Aussenac F; Tordo P; Bechinger B; Ouari O, *ChemPhysChem* 2017, 18, 2103. doi:10.1002/cphc.201700389 [PubMed: 28574169]
38. Salnikov ES; Sarrouj H; Reiter C; Aisenbrey C; Pura A; Aussenac F; Ouari O; Tordo P; Fedotenko I; Engelke F; Bechinger B, *J. Phys. Chem. B* 2015, 119, 14574. doi:10.1021/acs.jpcc.5b07341 [PubMed: 26487390]
39. Opella SJ; Marassi FM; Gesell JJ; Valente AP; Kim Y; Oblatt-Montal M; Montal M, *Nat. Struct. Biol* 1999, 6, 374. doi:10.1038/7610 [PubMed: 10201407]
40. Zeri AC; Mesleh MF; Nevzorov A; Opella SJ, *Proc. Natl. Acad. Sci* 2003, 100, 6458. doi:10.1073/pnas.1132059100 [PubMed: 12750469]
41. Park SH; De Angelis AA; Nevzorov AA; Wu CH; Opella SJ, *Biophys. J* 2006, 91, 3032. doi:10.1529/biophysj.106.087106 [PubMed: 16861273]
42. Park SH; Mrse AA; Nevzorov AA; Mesleh MF; Oblatt-Montal M; Montal M; Opella SJ, *J. Mol. Biol* 2003, 333, 409. doi:10.1016/j.jmb.2003.08.048 [PubMed: 14529626]
43. Das BB; Nothnagel HJ; Lu GJ; Son WS; Tian Y; Marassi FM; Opella SJ, *J. Am. Chem. Soc* 2012, 134, 2047. doi:10.1021/ja209464f [PubMed: 22217388]
44. De Angelis AA; Howell SC; Nevzorov AA; Opella SJ, *J. Am. Chem. Soc* 2006, 128, 12256. doi:10.1021/ja063640w [PubMed: 16967977]
45. Tian Y; Lu GJ; Marassi FM; Opella SJ, *J. Biomol. NMR* 2014, 60, 67. doi:10.1007/s10858-014-9852-0 [PubMed: 25103921]
46. Sharma M; Yi M; Dong H; Qin H; Peterson E; Busath DD; Zhou HX; Cross TA, *Science*. 2010, 330, 509. doi:10.1126/science.1191750 [PubMed: 20966252]
47. Mahalakshmi R; Marassi FM, *Biochemistry*. 2008, 47, 6531. doi:10.1021/bi800362b [PubMed: 18512961]
48. Dürr UHN; Waskell L; Ramamoorthy A, *Biochim. Biophys. Acta* 2007, 1768, 3235. doi:10.1016/j.bbamem.2007.08.007 [PubMed: 17945183]
49. Traaseth NJ; Shi L; Verardi R; Mullen DG; Barany G; Veglia G, *Proc. Natl. Acad. Sci* 2009, 106, 10165. doi:10.1073/pnas.0904290106 [PubMed: 19509339]
50. Verardi R; Shi L; Traaseth NJ; Walsh N; Veglia G, *Proc. Natl. Acad. Sci* 2011, 108, 9101. doi:10.1073/pnas.1016535108 [PubMed: 21576492]
51. Das N; Dai J; Hung I; Rajagopalan M; Zhou H-X; Cross TA, *Proc. Natl. Acad. Sci* 2015, 112, E119. doi:10.1073/pnas.1415908112 [PubMed: 25548160]
52. Aisenbrey C; Salnikov ES; Bechinger B, *J. Membr. Biol* 2019. doi:10.1007/s00232-019-00071-8
53. Salnikov ES; Aisenbrey C; Anantharamaiah GM; Bechinger B, *Chem. Phys. Lipids* 2019, 219, 58. doi:10.1016/j.chemphyslip.2019.01.012 [PubMed: 30711343]
54. Aisenbrey C; Kemayo-Koumkoua P; Salnikov ES; Glattard E; Bechinger B, *Biochemistry*. 2019, 58, 2782. doi:10.1021/acs.biochem.9b00375 [PubMed: 31120242]
55. Michalek M; Salnikov ES; Bechinger B, *Biophys. J* 2013, 105, 699. doi:10.1016/j.bpj.2013.06.030 [PubMed: 23931318]
56. Douat C; Aisenbrey C; Antunes S; Decossas M; Lambert O; Bechinger B; Kichler A; Guichard G, *Angewandte Chemie - International Edition* 2015, 54, 11133. doi:10.1002/anie.201504884 [PubMed: 26246005]
57. Wolf J; Aisenbrey C; Harmouche N; Raya J; Bertani P; Voievoda N; Süß R; Bechinger B, *Biophys. J* 2017, 113, 1290. doi:10.1016/j.bpj.2017.06.053 [PubMed: 28734478]
58. Gayen A; Leninger M; Traaseth NJ, *Nat. Chem. Biol* 2016, 12, 141. doi:10.1038/nchembio.1999 [PubMed: 26751516]
59. Rasmussen SGF; Choi HJ; Fung JJ; Pardon E; Casarosa P; Chae PS; Devree BT; Rosenbaum DM; Thian FS; Kobilka TS; Schnapp A; Konetzki I; Sunahara RK; Gellman SH; Pautsch A; Steyaert J; Weis WI; Kobilka BK, *Nature*. 2011, 469, 175. doi:10.1038/nature09648 [PubMed: 21228869]
60. Weber DK; Sani MA; Downton MT; Separovic F; Keene FR; Collins JG, *J. Am. Chem. Soc* 2016, 138, 15267. doi:10.1021/jacs.6b09996 [PubMed: 27786471]

61. Wang J; Denny J; Tian C; Kim S; Mo Y; Kovacs F; Song Z; Nishimura K; Gan Z; Fu R; Quine JR; Cross TA, *J. Magn. Reson* 2000, 144, 162. doi:10.1006/jmre.2000.2037 [PubMed: 10783287]
62. Murray DT; Hung I; Cross TA, *J. Magn. Reson* 2014, 240, 34. doi:10.1016/j.jmr.2013.12.014 [PubMed: 24509383]
63. Salnikov E; Bertani P; Raap J; Bechinger B, *J. Biomol. NMR* 2009, 45, 373. doi:10.1007/s10858-009-9380-5 [PubMed: 19823773]
64. Bertani P; Raya J; Bechinger B, *Solid State Nucl. Magn. Reson* 2014, 61–62, 15. doi:10.1016/j.ssnmr.2014.03.003
65. Holt A; Rougier L; Réat V; Jolibois F; Saurel O; Czaplicki J; Antoinette Killian J; Milon A, *Biophys. J* 2010, 98, 1864. doi:10.1016/j.bpj.2010.01.016 [PubMed: 20441750]
66. Separovic F; Pax R; Cornell B, *Mol. Phys* 1993, 78, 357. doi:10.1080/00268979300100281
67. Esteban-Martín S; Strandberg E; Fuertes G; Ulrich AS; Salgado J, *Biophys. J* 2009, 96, 3233. doi:10.1016/j.bpj.2008.12.3950 [PubMed: 19383467]
68. Molugu TR; Xu X; Leftin A; Lope-Piedrafita S; Martinez GV; Petrache HI; Brown MF, *Solid-State Deuterium NMR Spectroscopy of Membranes In Modern Magnetic Resonance*, Webb GA, Ed. Springer International Publishing: Cham, 2018; pp 581–603.
69. Humphrey W; Dalke A; Schulten K, *J. Mol. Graphics* 1996, 14, 33. doi:10.1016/0263-7855(96)00018-5
70. Lee W; Tonelli M; Markley JL, *Bioinformatics*. 2015, 31, 1325. doi:10.1093/bioinformatics/btu830 [PubMed: 25505092]
71. Shi L; Cembran A; Gao J; Veglia G, *Biophys. J* 2009, 96, 3648. doi:10.1016/j.bpj.2009.02.025 [PubMed: 19413970]
72. Jo S; Kim T; Iyer VG; Im W, *J. Comput. Chem* 2008, 29, 1859. doi:10.1002/jcc.20945 [PubMed: 18351591]
73. Wu EL; Cheng X; Jo S; Rui H; Song KC; Davila-Contreras EM; Qi Y; Lee J; Monje-Galvan V; Venable RM; Klauda JB; Im W, *J. Comput. Chem* 2014, 35, 1997. doi:10.1002/jcc.23702 [PubMed: 25130509]
74. Huang J; MacKerell AD, *J. Comput. Chem* 2013, 34, 2135. doi:10.1002/jcc.23354 [PubMed: 23832629]
75. Klauda JB; Venable RM; Freites JA; O'Connor JW; Tobias DJ; Mondragon-Ramirez C; Vorobyov I; MacKerell AD; Pastor RW, *J. Phys. Chem. B* 2010, 114, 7830. doi:10.1021/jp101759q [PubMed: 20496934]
76. Phillips JC; Braun R; Wang W; Gumbart J; Tajkhorshid E; Villa E; Chipot C; Skeel RD; Kalé L; Schulten K, *J. Comput. Chem* 2005, 26, 1781. doi:10.1002/jcc.20289 [PubMed: 16222654]
77. Mote KR; Gopinath T; Veglia G, *J. Biomol. NMR* 2013, 57, 91. doi:10.1007/s10858-013-9766-2 [PubMed: 23963722]
78. Mascioni A; Karim C; Barany G; Thomas DD; Veglia G, *Biochemistry*. 2002, 41, 475. doi:10.1021/bi011243m [PubMed: 11781085]
79. Rosenbaum DM; Zhang C; Lyons JA; Holl R; Aragao D; Arlow DH; Rasmussen S. r. G. F.; Choi HJ; Devree BT; Sunahara RK; Chae PS; Gellman SH; Dror RO; Shaw DE; Weis WI; Caffrey M; Gmeiner P; Kobilka BK, *Nature*. 2011, 469, 236. doi:10.1038/nature09665 [PubMed: 21228876]
80. Dror RO; Arlow DH; Maragakis P; Mildorf TJ; Pan AC; Xu H; Borhani DW; Shaw DE, *Proc. Natl. Acad. Sci* 2011, 108, 18684. doi:10.1073/pnas.1110499108 [PubMed: 22031696]
81. Helmus JJ; Jaroniec CP, *J. Biomol. NMR* 2013, 55, 355. doi:10.1007/s10858-013-9718-x [PubMed: 23456039]
82. Itkin A; Salnikov ES; Aisenbrey C; Raya J; Glattard E; Raussens V; Ruyschaert J-M; Bechinger B, *ACS Omega* 2017, 2. doi:10.1021/acsomega.7b00619
83. Quine JR; Achuthan S; Asbury T; Bertram R; Chapman MS; Hu J; Cross TA, *J. Magn. Reson* 2006, 179, 190. doi:10.1016/j.jmr.2005.12.002 [PubMed: 16413215]
84. Staus DP; Strachan RT; Manglik A; Pani B; Kahsai AW; Kim TH; Wingler LM; Ahn S; Chatterjee A; Masoudi A; Kruse AC; Pardon E; Steyaert J; Weis WI; Prosser RS; Kobilka BK; Costa T; Lefkowitz RJ, *Nature*. 2016, 535, 448. doi:10.1038/nature18636 [PubMed: 27409812]

85. Lacabanne D; Meier BH; Böckmann A, J. Biomol. NMR 2018, 71, 141. doi:10.1007/s10858-017-0156-z [PubMed: 29197975]
86. Verardi R; Traaseth NJ; Masterson LR; Vostrikov VV; Veglia G, Isotope Labeling for Solution and Solid-State NMR Spectroscopy of Membrane Proteins In Isotope labeling in Biomolecular NMR, Atreya HS, Ed. Springer Netherlands: Dordrecht, 2012; Vol. 992, pp 35–62.
87. Prosser RS; Hunt SA; DiNatale JA; Vold RR, J. Am. Chem. Soc 1996, 118, 269. doi:10.1021/ja953598x
88. Park SH; Mrse AA; Nevzorov AA; De Angelis AA; Opella SJ, J. Magn. Reson 2006, 178, 162. doi:10.1016/j.jmr.2005.08.008 [PubMed: 16213759]
89. Tesch DM; Pourmoazzen Z; Awosanya EO; Nevzorov AA, Appl. Magn. Reson 2018, 49, 1335. doi:10.1007/s00723-018-1056-4
90. Buffy JJ; Traaseth NJ; Mascioni A; Gor'kov PL; Chekmenev EY; Brey WW; Veglia G, Biochemistry. 2006, 45, 10939. doi:10.1021/bi060728d [PubMed: 16953579]
91. Kim S; Cross TA, Biophys. J 2002, 83, 2084. doi:10.1016/S0006-3495(02)73969-6 [PubMed: 12324426]
92. Ravula T; Hardin NZ; Ramadugu SK; Cox SJ; Ramamoorthy A, Angew. Chem. Int. Ed 2018, 57, 1342. doi:10.1002/anie.201712017
93. Ravula T; Hardin NZ; Ramamoorthy A, Chem. Phys. Lipids 2019, 219, 45. doi:10.1016/j.chemphyslip.2019.01.010 [PubMed: 30707909]
94. Harmouche N; Bechinger B, Biophys. J 2018, 115, 1033. doi:10.1016/j.bpj.2018.08.009 [PubMed: 30195937]





Figure 1:
 A) MD simulation snapshot of SLN embedded in a lipid bilayer with CS tensor components and the DC vectors projected onto the amide plane of each residue. B) Correlation plots between MD-derived and experimental CS and DC values. C) MD-derived CS-DC correlations (red triangles) overlaid onto an experimental SE-SAMPI4 spectrum of SLN in *unflipped* bicelles, where the normal of the bilayer is perpendicular to the direction of the static field (\mathbf{B}_0).^[25]

**Figure 2:**

A) Simulated ^{15}N - ^1H SLF spectrum (14.1 T; 50 Hz linewidths) of the β_2 -adrenergic GPCR back-calculated from 150 ns of equilibrated MD trajectory (red contours). Ideal PISA wheels fit to helical segments are overlaid as black lines. B) Extraction of TM7 and H8 residues for clear comparison to PISA fits. C) Nomenclature of helical segments. D) Convergence of SLF peak positions with time after 50 ns of initial equilibration. E) Per-residue contributions to the final SLF drift score after 200 ns of simulation.